1. Tardive Dyskinesia - Pipeline Review, Q3 2011
Tardive Dyskinesia - Pipeline Review, Q3 2011
Summary
Global Markets Direct’s, 'Tardive Dyskinesia - Pipeline Review, Q3 2011', provides
an overview of the Tardive Dyskinesia therapeutic pipeline. This report provides
information on the therapeutic development for Tardive Dyskinesia, complete with
latest updates, and special features on late-stage and discontinued projects. It also
reviews key players involved in the therapeutic development for Tardive Dyskinesia.
'Tardive Dyskinesia - Pipeline Review, Q3 2011' is built using data and information
sourced from Global Markets Direct’s proprietary databases, Company/University
websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by
Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Tardive Dyskinesia.
- A review of the Tardive Dyskinesia products under development by companies and
universities/research institutes based on information derived from company and
industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
- Coverage of the Tardive Dyskinesia pipeline on the basis of therapeutic class,
route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description,
mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Browse All Pharmaceuticals Market Research Reports
Reasons to buy
- Identify and understand important and diverse types of therapeutics under
development for Tardive Dyskinesia.
- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most
promising pipeline.
- Devise corrective measures for pipeline projects by understanding Tardive
Dyskinesia pipeline depth and focus of Tardive Dyskinesia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand

2. business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Tardive Dyskinesia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Tardive Dyskinesia 7
Tardive Dyskinesia Therapeutics under Development by Companies 9
Tardive Dyskinesia Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Tardive Dyskinesia Therapeutics - Products under Development by Companies 13
Tardive Dyskinesia Therapeutics - Products under Investigation by
Universities/Institutes 14
Companies Involved in Tardive Dyskinesia Therapeutics Development 15
Neurocrine Biosciences, Inc. 15
Medicure Inc. 15
Tardive Dyskinesia - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
NBI-98854 - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
TARDOXAL - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Piracetam - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Tardive Dyskinesia Therapeutics – Drug Profile Updates 24
Tardive Dyskinesia Therapeutics - Discontinued Products 25
Tardive Dyskinesia - Featured News 26
Jun 23, 2011: Neurocrine Biosciences Announces Notice Of Allowance For

3. Composition Of Matter Patent On VMAT2 Inhibitor 26
Apr 05, 2011: Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial
For VMAT2 Inhibitor 26
Oct 18, 2010: Neurocrine Completes Reports Second Phase I Clinical Trial Of NBI-
98854 27
Apr 13, 2010: Neurocrine Biosciences Announces The Initiation Of Second VMAT2
Phase I Clinical Trial 28
Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial
28
Dec 21, 2009: Neurocrine Announces VMAT2 Inhibitor 29
Mar 11, 2009: Medicure Inc Announces Regulatory Approval Of A Phase II Clinical
Trial Of Avastrem For The Treatment Of Tardive Dyskinesia Medicure Inc.
Announces Regulatory Approval of a Phase II Clinical Trial of Avastrem for the
Treatment o 29
Jan 12, 2009: Medicure Announces Regulatory Approval Of A Phase II Clinical TriaL
Of Avastrem For The Treatment Of Tardive Dyskinesia 30
Apr 03, 2008: Proximagen Neuroscience Plc - Interim results for the six months
ended 31 May 2008 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 32
Contact Us 32
Disclaimer 32
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and
in-depth market research studies & analysis of over 5000 micro markets. We
provide 24/7 online and offline support to our customers. Get in touch with us for
your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page
http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004
E-mail: sales@reportsandreports.com
http://www.reportsandreports.com
Visit our Market Research Blog